Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (PHIO): 1 pipeline candidate · ~13 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
12.8 months
D/E 0.06 · 0% dilution
Lead: Phase 1
1 candidate
N/A
2 buys · 0 sells (180d)
A transparent, data-derived signal for Phio Pharmaceuticals Corp.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$12.8M
Cash
$17.0M
Quarterly Burn
$4.0M
Runway
12.8 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| ph-762 | Phase 1 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
21
Total value held
$722K
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 159,706 | $195K |
| geode capital management, llc | 147,254 | $180K |
| jane street group, llc | 119,189 | $145K |
| vanguard fiduciary trust co | 38,169 | $47K |
| two sigma investments, lp | 32,495 | $40K |
| xtx topco ltd | 24,868 | $30K |
| northern trust corp | 23,758 | $29K |
| two sigma securities, llc | 15,224 | $19K |
| captrust financial advisors | 10,000 | $12K |
| tower research capital llc (trc) | 7,620 | $9K |
Showing top 10 of 21 institutional holders of Phio Pharmaceuticals Corp.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Phio Pharmaceuticals Corp.'s pipeline?
Phio Pharmaceuticals Corp. (PHIO) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Phio Pharmaceuticals Corp.'s lead drug candidate?
Phio Pharmaceuticals Corp.'s most advanced tracked candidate is ph-762 (Phase 1) for Squamous Cell Carcinoma of the Skin.
What is Phio Pharmaceuticals Corp.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Phio Pharmaceuticals Corp. has approximately 12.8 months of cash runway.
What is Phio Pharmaceuticals Corp.'s market capitalization?
Phio Pharmaceuticals Corp.'s market capitalization is approximately $12.8M.
Who is the CEO of Phio Pharmaceuticals Corp.?
Mr. Robert J. Bitterman is the chief executive officer of Phio Pharmaceuticals Corp. (PHIO).
Get the full picture on Phio Pharmaceuticals Corp.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.